Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.
Ten patients with head trauma received an intravenous bolus of sufentanil (2 micrograms kg-1) followed at 30 min by infusion of sufentanil (median 150 micrograms h-1) and midazolam (median 9.0 mg h-1) over 48 h. Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1. Decreases in intracranial pressure (ICP) (from 16.1 +/- 1.7 to 10.8 +/- 1.3 mm Hg; P < 0.05) and mean arterial blood pressure (MAP) (from 85.5 +/- 3.9 to 80.2 +/- 4.9 mm Hg; P < 0.05) were observed within 15 min of the bolus injection of sufentanil and remained unchanged thereafter. Thus, cerebral perfusion pressure (CPP = MAP-ICP) was stable.
Scholz
J
J
Department of Anaesthesiology, University of Hamburg, University Hospital Eppendorf, Germany.
Bause
H
H
Schulz
M
M
Klotz
U
U
Krishna
D R
DR
Pohl
S
S
Schulte am Esch
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D006259:Craniocerebral Trauma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007427:Intracranial Pressure / Q000187:drug effects*; D008297:Male; D008657:Metabolic Clearance Rate; D008874:Midazolam / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D011863:Radioimmunoassay; D012044:Regression Analysis; D017409:Sufentanil / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use
D017409:Sufentanil; D008874:Midazolam